<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Activating point mutations in CBL have recently been identified in diverse subtypes of myeloid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Because detailed clinical and hematological characteristics of CBL-mutated cases is lacking, we screened 156 BCR-ABL and JAK2 V617F negative patients with myeloproliferative <z:hpo ids='HP_0002664'>neoplasms</z:hpo> (MPN) and <z:e sem="disease" ids="C0410000" disease_type="Disease or Syndrome" abbrv="">overlap syndromes</z:e> between <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and MPN (MPS/MPN) for mutations in exons 8 and 9 of CBL by denaturing high-performance liquid chromatography and direct sequencing </plain></SENT>
<SENT sid="2" pm="."><plain>CBL mutations were identified in 16/156 patients (10%), of which five also carried mutations in EZH2 (n = 3) and TET2 (n = 2) </plain></SENT>
<SENT sid="3" pm="."><plain>Comprehensive clinical and hematological characteristics were available from 13/16 patients (81%) </plain></SENT>
<SENT sid="4" pm="."><plain>In addition to <z:hpo ids='HP_0001744'>splenomegaly</z:hpo> (77%), striking common hematological features were <z:mp ids='MP_0005481'>CML</z:mp>-like left-shifted <z:hpo ids='HP_0001974'>leukocytosis</z:hpo> (85%) with <z:mp ids='MP_0000220'>monocytosis</z:mp> (85%), <z:hpo ids='HP_0001903'>anemia</z:hpo> (100%), and <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> (62%) </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0001894'>Thrombocytosis</z:hpo> was not observed in any patient </plain></SENT>
<SENT sid="6" pm="."><plain>Relevant bone marrow features (n = 12) included hypercellularity (92%) with marked granulopoiesis (92%), nonclustered microlobulated megakaryocytes (83%), and marrow <z:mp ids='MP_0003045'>fibrosis</z:mp> (83%) </plain></SENT>
<SENT sid="7" pm="."><plain>Nine <z:hpo ids='HP_0011420'>deaths</z:hpo> (progression to secondary <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>/<z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast phase</z:e>, n = 7; cytopenia complications, n = 2) were recorded </plain></SENT>
<SENT sid="8" pm="."><plain>Three-year survival rate was 27%, possibly indicating poor prognosis of CBL mutated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/MPN patients </plain></SENT>
</text></document>